Acurx Pharmaceuticals
ACXP
21 hedge funds and large institutions have $674K invested in Acurx Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
125% more capital inflows, than outflows
Capital inflows: $377K | Capital outflows: $168K
17% more funds holding
Funds holding: 18 → 21 (+3)
1.51% more ownership
Funds ownership: 4.85% → 6.37% (+1.5%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$125K |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$56.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$35.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$17.4K |
| 5 |
Westside Investment Management
Santa Monica,
California
|
+$4.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$103K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$42.1K |
| 3 |
Prospect Financial Services
Melville,
New York
|
-$17.2K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$5.26K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$108 |
ACXP Hedge Fund Activity: Q1 2026 in Review
21 of the 8,220 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q1 2026, worth a combined $674K — up 95% from $345K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ACXP positions and 3 closed out — a net gain of 4 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Jane Street, adding an estimated $125K. The largest seller was Millennium Management, exiting entirely with an estimated $103K sold.
- 21 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q1 2026, up from 18 in Q4 2025.
- Funds reported $674K of Acurx Pharmaceuticals stock for Q1 2026, up 95% quarter-over-quarter.
- 7 funds opened new Acurx Pharmaceuticals positions in Q1 2026 and 3 closed out, a net change of +4 holders.
- The largest Acurx Pharmaceuticals buyer in Q1 2026 was Jane Street, an estimated $125K added.
- The largest Acurx Pharmaceuticals seller in Q1 2026 was Millennium Management, an estimated $103K sold.
Based on aggregated 13F filings for Q1 2026.